ctDNA testing effectively stratifies Merkel cell carcinoma patients into high and low recurrence risk categories, influencing surveillance strategies. The study's cohorts revealed significant ...

They show that just over 90% of muscle invasive bladder cancer (MIBC) patients with a negative circulating DNA (ctDNA) test following surgery, which remained negative on follow up, did not relapse.

The results of a ctDNA test can be therapeutic. Two-thirds of cancer survivors suffer from fear of cancer recurrence (FCR) making it the most common long term complication from a cancer diagnosis.

The largest study to date to assess the clinical value of concurrently testing tissue and circulating tumour DNA (ctDNA), highlights the usefulness of this dual approach for identifying targetable ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

The test, made by Roche, the pharmaceutical firm, will be accurate for non-small cell cancers, which make up around four in five of the UK’s 34,000 yearly diagnoses. They are 100 per cent accurate ...

The studies will evaluate the use of circulating tumour DNA (ctDNA) in monitoring treatment response in breast cancer patients. The Precise MRD test is a genome sequencing (WGS) based test that ...

Most of the currently available circulating tumor DNA (ctDNA) technologies provide a high level of diagnostic accuracy for detecting human papillomavirus (HPV)-associated oropharyngeal squamous ...

Professor Nicholas Turner, Professor of Molecular Oncology at the ICR, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said: “Testing a patient’s blood for ctDNA will ...

Therefore, testing a patient’s blood for ctDNA will allow clinicians to diagnose the return of cancer at the very earliest stage. Previous studies have shown that ctDNA blood tests can identify ...